Recruiting

Immunosuppressive DrugsUse of Immunosuppressive Therapy for Sarcoidosis

Sponsor:

University of Cincinnati

Code:

NCT02356445

Conditions

Sarcoidosis

Eligibility Criteria

Sex: All

Age: 15 - 70+

Healthy Volunteers: Not accepted

Interventions

Cytotoxic drug

Study Details

Brief summary:

Retrospective review of the outcome of use of immunosuppressive drugs in treatment of sarcoidosis

Conditions

Sarcoidosis

Study ID

NCT02356445

Start date

Nov, 2014

Status verified date

Aug, 2017

Completion date

Dec, 2018

Anticipated

Primary completion date

Nov, 2018

Anticipated

Eligibility Criteria

Sex: All

Age: 15 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

Any patient treated for sarcoidosis

Exclusion Criteria:

None

Study Design

Enrollment

2000 participants

Anticipated

Interventions and Outcome Measures

Arms

Cytotoxic drug

Patients treated for sarcoidosis

Interventions

Cytotoxic drug

Observe patients versus treatment type

Primary outcome measure

Clinical Outcome [ Time Frame: 2 years ]

Central Contacts and Locations

Central contacts

Robert P Baughman, MD

513-584-5225 bob.baughman@uc.edu

Felicia Thompson

513-584-5226 thompsonf@ucmail.uc.edu

Locations

University of Cincinnati

Recruiting

Cincinnati, Ohio, United States, 45267

Contacts

Robert P Baughman, MD

513-584-5225 bob.baughman@uc.edu

Elyse E Lower

513-584-3829 ELower@ohcmail.com

More Information

Sponsor

University of Cincinnati

Last update posted

Aug 14, 2017

Last verified

Aug, 2017

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of Cincinnati on 2017-08-14.